Pentyline solution for injection 100 mg ampoule 5 ml No. 5

Indications for use:
Pentylin is intended for the treatment of patients suffering from circulatory disorders, as well as conditions associated with impaired macro- and microcirculation, including:
Chronic occlusive circulatory disorders in the arteries of the lower extremities, as well as associated circulatory disorders in peripheral vessels (including in patients with intermittent claudication).
Ischemic stroke and post-stroke conditions, ischemic disorders of cerebral circulation, atherosclerosis of cerebral vessels, which is accompanied by headache, dizziness, memory and sleep disorders.

Ischemic heart disease, dyscirculatory encephalopathy, angiopathy in patients with diabetes. Pentyline is also prescribed to patients who have suffered a myocardial infarction.
Erectile dysfunction of vascular origin.
Circulatory disorders in the choroid of the eye and retina, acute form of ischemic neuropathy of the optic nerve.
Pentyline is also prescribed to patients with otosclerosis, a pathology of the vessels of the inner ear, which is accompanied by degenerative changes and hearing loss.
Pentoxifylline can be prescribed to patients with bronchial asthma and chronic obstructive pulmonary disease.


Method of application:
Prolonged-release tablets:
Pentylin in tablet form is intended for oral use. The tablet should be swallowed whole, crushing and chewing of the tablet is not allowed. To achieve the maximum therapeutic effect, the drug should be taken at the same time of day. To reduce the risk of side effects, Pentylin should be taken after meals. The duration of therapy and the dose of pentoxifylline are determined by the attending physician.
Adults are usually recommended to take 1 prolonged-release tablet 3 times a day. After the patient's condition improves, they are switched to taking 1 prolonged-release tablet 2 times a day.
Adults with mild forms of the disease are usually recommended to take 1 extended-release tablet per day.
A daily dose of more than 1200 mg of pentoxifylline does not lead to an increase in the therapeutic effect, but significantly increases the risk of developing undesirable effects.
The therapeutic effect develops within 2-4 weeks. The minimum course of therapy is 8 weeks.

Solution for injection:
Pentyline in solution form is intended for parenteral use. Only intravenous jet or drip administration of the solution is allowed. To prepare the solution for infusions, Ringer's lactate solution, 5% glucose solution or 0.9% sodium chloride solution are used. The duration of therapy and the dose of pentoxifylline are determined by the doctor.
It is usually recommended to administer 100-600 mg of pentoxifylline diluted in 100-500 ml of a compatible infusion solution, 1-2 times a day. The rate of administration should not exceed 100 mg of active substance per hour.
In severe cases, it is recommended to administer 0.6 mg/kg of body weight per hour (but not more than 1200 mg/day) as an infusion for 24 hours. The average volume of fluid administered is about 1.0-1.5 l per day.
At the doctor's discretion, it is also allowed to administer 5 ml of the drug intravenously (injection time not less than 5 minutes). During the injection, the patient should be in a horizontal position.
After the patient's condition improves, they switch to oral administration of the drug.
The maximum daily dose of pentoxifylline (including parenteral and oral administration) is 1200 mg.
For patients with impaired renal function with creatinine clearance less than 30 ml/min, the dose of pentoxifylline should be adjusted (the dose is selected individually, usually it is 50-70% of the standard dose).


Side effects:
The drug Pentilin may cause the development of the following undesirable effects:
From the side of the blood and cardiovascular system: hyperemia of the face and upper body, heart rhythm disturbances, angina pectoris, decreased blood pressure, thrombocytopenia, increased prothrombin time, leukopenia.
From the side of the central and peripheral nervous system: sleep and wakefulness disorders, headache, dizziness, excessive excitement or weakness.
Gastrointestinal tract: pain and discomfort in the epigastric region, anorexia, nausea, vomiting, flatulence, cholestasis, increased liver enzymes.
Allergic reactions: skin rash, itching, urticaria, angioedema, bronchospasm, anaphylactic shock.
Others: decreased visual acuity, increased sweating.
If side effects develop, it is recommended to adjust the dose of the drug; if side effects are severe, the drug should be discontinued.


Caution should be exercised when prescribing pentoxifylline to patients with diabetes mellitus, arterial hypotension (including those at risk of hypotension), renal impairment with creatinine clearance less than 30 ml/min, and patients with an increased risk of bleeding.
Pentylin can be prescribed only after a careful risk/benefit assessment to patients with myocardial infarction, chronic heart failure, as well as impaired liver function (for the injectable form of the drug).
During the period of drug therapy, special caution should be exercised by patients who drive a car or operate potentially dangerous mechanisms.


pregnancy:
Pentilin is contraindicated for pregnant women. During treatment with the drug, women of reproductive age should use reliable contraception, and pentoxifylline should be discontinued if pregnancy is planned or occurs.
If it is necessary to take Pentilin during lactation, it is recommended to discontinue breastfeeding after consulting a doctor.


Interaction with other drugs:
When prescribing the drug to patients receiving therapy with antihypertensive agents (especially angiotensin-converting enzyme inhibitors), blood pressure should be monitored and, if necessary, the dose of antihypertensive agents should be adjusted.
The simultaneous use of Pentilin with anticoagulants, ketorolac and meloxicam increases the risk of bleeding.
Cimetidine and ciprofloxacin, when used simultaneously with the drug Pentilin, contribute to an increase in plasma concentrations of pentoxifylline.
Pentyline increases plasma concentrations of theophylline when used simultaneously.
The drug enhances the effectiveness of nitrates.
With the simultaneous use of hypoglycemic agents and intravenous administration of high doses of Pentilin, an increase in the hypoglycemic effect of antidiabetic drugs is noted.


Overdose:
When using excessive doses of the drug Pentilin, patients develop arterial hypotension, flushing of the face and upper body, nausea, hyperthermia, dizziness and tachycardia. With a further increase in the dose, the development of areflexia, loss of consciousness, excessive excitement and tonic-clonic seizures was noted. In some cases, with an overdose of pentoxifylline, the development of gastrointestinal bleeding was noted, a symptom of which is vomiting the color of coffee grounds.
In case of overdose, the drug is discontinued. In case of taking excessive doses of the oral form of the drug Pentilin, gastric lavage and the use of enterosorbents are indicated. In addition, regardless of the form of the drug, symptomatic therapy is indicated, as well as measures aimed at maintaining blood pressure and respiratory function.


Release form:
Prolonged-release tablets are packed in 10 pieces in contour blister packs, 2 contour blister packs are placed in a cardboard pack.
Solution for injection in 5 ml ampoules, 5 ampoules placed in a cardboard pack.


Storage conditions:
The drug, regardless of the form of release, should be stored in dry rooms at a temperature of 15 to 25 degrees Celsius.
If storage conditions are observed, the drug is suitable for 5 years.


Synonyms:
Trental, Agapurin.


composition:
1 prolonged-release tablet of the drug Pentilin contains:
Pentoxifylline - 400mg;
Additional substances.

1 ml of Pentylin injection solution contains:
Pentoxifylline - 20mg;
Additional substances.